Scorpion toxins: Tools for studying K+ channels

Toxicon

Volumn 36, Issue 11, 1998, Pages 1641-1650

  Garcia, Maria L ^a   Hanner, Markus ^a   Kaczorowski, Gregory J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL; PROTEIN SUBUNIT; SCORPION VENOM;

CONFERENCE PAPER; HUMAN; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN STRUCTURE; SARCOLEMMA; T LYMPHOCYTE; TOXIN ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; AORTA; CARBOHYDRATE SEQUENCE; CATTLE; CHARYBDOTOXIN; HUMANS; KV1.3 POTASSIUM CHANNEL; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH, VASCULAR; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; POTASSIUM CHANNELS, VOLTAGE-GATED; SCORPION VENOMS; SCORPIONS; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES;

EID: 0031795797     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-0101(98)00157-3     Document Type: Conference Paper

References (44)

1. Aiyar J., Rizzi J. P., Gutman G. A., Chandy K. G. The signature sequence of voltage-gated potassium channels projects into the external vestibule. J. Biol. Chem. 271:1996;31013.
2. + channel revealed by the NMR-derived structures of scorption toxins. Neuron. 15:1995;1169.
3. Ks cardiac potassium current. Nature. 384:1996;78.
4. 1H-NMR. Charybdotoxin possesses a structural motif found in other scorpion toxins. Eur. J. Biochem. 196:1991;19.
5. Bontems F., Roumestand C., Gilquin B., Menez A., Toma F. Refined structure of charybdotoxin: common motifs in scorpion toxins and insect defensins. Science. 254:1991;1521.
6. + channels are required for T lymphocyte activation. J. Exp. Med. 160:1984;369.
7. Chandy, K. G. and Gutman, G. A. (1995) Voltage-gated potassium channel genes. In Handbook of Receptors and Channels, ed. R. A. North, CRC Press, Boca Raton.
8. Dauplais M., Gilquin B., Possani L. D., Gurrola-Briones G., Roumestand C., Menez A. Determination of the three-dimensional solution structure of noxiustoxin: analysis of structural differences with related short-chain scorpion toxins. Biochemistry. 34:1995;16563.
9. + channels in human T lymphocytes: a role in mitogenesis? Nature. 307:1984;465.
10. Galvez A., Gimenez-Gallego G., Reuben J. P., Roy-Contancin L., Feigenbaum P., Kaczorowski G. J., Garcia M. L. Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J. Biol. Chem. 265:1990;11083.
11. Garcia-Calvo M., Knaus H.-G., McManus O. B., Giangiacomo K. M., Kaczorowski G. J., Garcia M. L. Purification and reconstitution of the high-conductance calcium-activated potassium channel from tracheal smooth muscle. J. Biol. Chem. 269:1994;676.
12. Garcia, M. L., Hanner, M., Knaus, H.-G., Koch, R., Schmalhofer, W., Slaughter, R. S. and Kaczorowski, G. S. (1996) Pharmacology of potassium channels. In Advances in Pharmacology, eds J. T. August, M. W. Anders, F. Murad and J. T. Coyle. Academic Press, Inc., San Diego.
13. + channels: structure-function analysis. Pfluegers Arch. Eur. J. Physiol. 434:1997;R83.
14. Garcia M. L., Hanner M., Knaus H.-G., Koch R., Schmalhofer W., Slaughter R. S., Kaczorowski G. J. Pharmacology of potassium channels. Advances in Pharmacology. 39:1997;425.
15. Garcia-Calvo M., Leonard R. J., Novick J., Stevens S. P., Schmalhofer W., Kaczorowski G. J., Garcia M. L. Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. J. Biol. Chem. 268:1993;18866.
16. + channel: peptide and channel residues mediating molecular recognition. Neuron. 12:1994;1377.
17. Hanner, M., Schmalhofer, W. A., Munujos, P., Knaus, H.-G., Kaczorowski, G. J. and Garcia, M. L. (1997) The β subunit of the high conductance calcium-activated potassium channel contributes to the high affinity receptor for charybdotoxin. Proc. Natl. Acad. Sci. U.S.A., 94, 2853.
18. + channel pore through mutant cycles with a peptide inhibitor. Science. 268:1995;307.
19. 1H nuclear magnetic resonance spectroscopy. Biochemistry. 31:1992;8151.
20. 15N triple-resonance nuclear magnetic resonance spectroscopy. Biochemistry. 33:1994;15061.
21. + channel. J. Biol. Chem. 269:1994;23336.
22. + channel from smooth muscle. J. Biol. Chem. 269:1994;17274.
23. + channels. Biochemistry. 33:1994;5819.
24. + channels. J. Biol. Chem. 272:1997;27577.
25. Koo G. C., Blake J. T., Talento A., Nguyen M., Lin S., Sirotina A., Shah K., Mulvany K., Cunningham D. H. P. Jr., Wunderler D. L., McManus O. B., Slaughter R., Bugianesi R., Felix J., Garcia M., Williamson J., Kaczorowski G., Sigal N. H., Springer M. S., Feeney W. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 158:1997;5120.
26. 1, a novel peptide derived from Centruroides limbatus venom. J. Biol. Chem. in press.
27. 125I]Iberiotoxin-D19Y/Y36F, the first selective, high specific activity radioligand for high-conductance calcium-activated potassium channels. Biochemistry. 36:1997;1943.
28. Krezel A. M., Kasibhatla C., Hidalgo P., MacKinnon R., Wagner G. Solution structure of the potassium channel inhibitor agitoxin 2: caliper for probing channel geometry. Protein Science. 4:1995;1478.
29. + channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10094.
30. Lin C. S., Boltz R. C., Blake J. T., Nguyen M., Talento A., Fischer P. A., Springer M. S., Sigal N. H., Slaughter R. S., Garcia M. L., Kaczorowski G. J., Koo G. C. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J. Exp. Med. 177:1993;637.
31. McManus O. B., Harris G. H., Giangiacomo K. M., Feigenbaum P., Reuben J. P., Addy M. E., Burka J. F., Kaczorowski G. J., Garcia M. L. An activator of calcium-dependent potassium channels isolated from a medicinal herb. Biochemistry. 32:1993;6128.
32. McManus O. B., Helms L. M. H., Pallanck L., Ganetzky B., Swanson R., Leonard R. J. Functional role of the β subunit of high-conductance calcium-activated potassium channels. Neuron. 14:1995;1.
33. Meera P., Wallner M., Ottolia M., Adelman J. P., Kaczorowski G., Garcia M. L., Toro L. Differential effects of the maxi-K β subunit on the α subunit of human and Drosophila expressed in Xenopus laevis oocytes. Biophys. J. 68:1995;3a.
34. Munujos P., Knaus H.-G., Kaczorowski G. J., Garcia M. L. Crosslinking of charybdotoxin to high-conductance calcium-activated potassium channels: identification of the covalently modified toxin residue. Biochemistry. 34:1995;10771.
35. + channel blocking peptide, purified from the venom of the scorpion Centruroides noxius Hoffmann. Carlsberg Res. Commun. 47:1982;285.
36. Price M., Lee S. C., Deutsch C. Charybdotoxin inhibits proliferation and IL2 production in human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 86:1989;10171.
37. + channel selectivity filter by mutant cycle-based structure analysis. Neuron. 16:1996;131.
38. + channels. J. Biol. Chem. 272:1997;24371.
39. Ks potassium channel. Nature. 384:1996;80.
40. Shimony E., Sun T., Kolmakova-Partensky L., Miller C. Engineering a uniquely reactive thiol into a cysteine-rich peptide. Protein Engineering. 7:1994;503.
41. Singh S. B., Goetz M. A., Zink D. L., Dombrowski A. W., Polishook J. D., Garcia M. L., Schmalhofer W., McManus O. B., Kaczorowski G. J. Maxikdiol: a novel dihydroxyisoprimane as an agonist of maxi-K channels. J. Chem. Soc. Perkin Trans. 1:1994;3349.
42. + channel vestibule. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9509.
43. Vazquez J., Feigenbaum P., King V. F., Kaczorowski G. J., Garcia M. L. Characterization of high affinity binding sites for charybdotoxin in synaptic plasma membranes from rat brain: evidence for a direct association with an inactivating, voltage-dependent, potassium channel. J. Biol. Chem. 265:1990;15564.
44. Wei A., Jegla T., Salkoff L. Eight potassium channel families revealed by the C. elgans genome project. Neuropharmacology. 35:1996;805.